Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea.
The purpose of this study was to evaluate the immunogenicity and safety of Salmonella Typhi Vi capsular polysaccharide vaccine (Vi vaccine) in Korea. The immunogenicity of a single dose of Vi vaccine was evaluated in 157 subjects (75 children and 82 adults) before and at 1, 6, and 12 months after vaccination. Immunogenicity was measured with a passive hemagglutination assay (PHA), quantified as geometric mean titers (GMTs) and seroconversion rates. The safety of the vaccine was investigated by determining adverse reactions occurring within 4 h, 3 days, and 1 month after injection. The seroconversion rate for children and adults 1 month after vaccination was 96.92% and 89.02%, respectively. In the case of children, the GMTs of Vi antibodies before vaccination were 5.87 +/- 1.34 and 142.59 +/- 2.39 at one month after vaccination. For adults, the GMTs before and one month after vaccination were 5.58 +/- 1.28 and 58.56 +/- 3.67, respectively. Vi antibodies persisted for as long as 6 and 12 months after vaccination. All adverse reactions in adults and children were minor and did not require treatment. The Vi CPS vaccine was safe and immunogenic in adults and children older than 5 years.
Lim
Sang-Min
SM
Central Research Institute, Boryung Pharm. Co. Ltd., Ansan 425-120, Korea.
Jung
Hahn-Sun
HS
Kim
Min Ja
MJ
Park
Dae-Won
DW
Kim
Woo-Joo
WJ
Cheong
Hee-Jin
HJ
Park
Seung-Chul
SC
Lee
Kwang-Chul
KC
Shin
Young-Kyoo
YK
Tan
Hyun Kwang
HK
Kim
Sang-Lin
SL
Sohn
Jang Wook
JW
D000293:Adolescent; D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007114:Immunization; D008297:Male; D008875:Middle Aged; D011135:Polysaccharides, Bacterial / Q000009:adverse effects / Q000276:immunology*; D011358:Product Surveillance, Postmarketing; D014436:Typhoid-Paratyphoid Vaccines / Q000009:adverse effects / Q000276:immunology*
D000907:Antibodies, Bacterial; D011135:Polysaccharides, Bacterial; D014436:Typhoid-Paratyphoid Vaccines; C057664:Vi polysaccharide vaccine, typhoid